{"id":1190,"date":"2023-11-13T23:35:42","date_gmt":"2023-11-13T23:35:42","guid":{"rendered":"https:\/\/oncologytweetorials-ce.com\/?p=1190"},"modified":"2023-11-14T12:49:11","modified_gmt":"2023-11-14T12:49:11","slug":"endometrial3_esgo2023","status":"publish","type":"post","link":"https:\/\/oncologytweetorials-ce.com\/endometrial3_esgo2023\/","title":{"rendered":"ESGO23 Update on Advanced and Recurrent Endometrial Cancer Management"},"content":{"rendered":"\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">2) This 3\u20e3 rd installment addresses key pertinent data from <a href=\"https:\/\/twitter.com\/hashtag\/ESGO2023?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO2023<\/a>, held in <a href=\"https:\/\/twitter.com\/hashtag\/Istanbul?src=hash&amp;ref_src=twsrc%5Etfw\">#Istanbul<\/a> last month.<a href=\"https:\/\/twitter.com\/hashtag\/FOAMed?src=hash&amp;ref_src=twsrc%5Etfw\">#FOAMed<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/onctwitter?src=hash&amp;ref_src=twsrc%5Etfw\">#onctwitter<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/ecsm?src=hash&amp;ref_src=twsrc%5Etfw\">#ecsm<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/gyncancersm?src=hash&amp;ref_src=twsrc%5Etfw\">#gyncancersm<\/a><br>Follow us for regular <a href=\"https:\/\/twitter.com\/hashtag\/accredited?src=hash&amp;ref_src=twsrc%5Etfw\">#accredited<\/a> updates across <a href=\"https:\/\/twitter.com\/hashtag\/oncology?src=hash&amp;ref_src=twsrc%5Etfw\">#oncology<\/a>, all delivered right here on X ! <a href=\"https:\/\/t.co\/Rl9t8Jy4YP\">pic.twitter.com\/Rl9t8Jy4YP<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403962047025502?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">4a) <a href=\"https:\/\/twitter.com\/ESGO_society?ref_src=twsrc%5Etfw\">@ESGO_society<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/ESGO23?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO23<\/a> lived up to its billing as the European Voice of <a href=\"https:\/\/twitter.com\/hashtag\/Gynecological?src=hash&amp;ref_src=twsrc%5Etfw\">#Gynecological<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/Oncology?src=hash&amp;ref_src=twsrc%5Etfw\">#Oncology<\/a>. The well-attended meeting hosted the presentation of cutting-edge data across multiple topics, including advanced <a href=\"https:\/\/twitter.com\/hashtag\/endometrial?src=hash&amp;ref_src=twsrc%5Etfw\">#endometrial<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a>!<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403965507272935?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">5) <a href=\"https:\/\/twitter.com\/hashtag\/EndometrialCancer?src=hash&amp;ref_src=twsrc%5Etfw\">#EndometrialCancer<\/a> is the 6th most common cancer in \ud83d\udebaworldwide. Incidence &amp; mortality are both \u2b06\ufe0f! Localized dz often curable but poor outcomes in advanced dz so more treatment options needed. <a href=\"https:\/\/t.co\/VWkL98vpXh\">pic.twitter.com\/VWkL98vpXh<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403969445830952?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">6b) As a reminder, <a href=\"https:\/\/twitter.com\/hashtag\/RUBY?src=hash&amp;ref_src=twsrc%5Etfw\">#RUBY<\/a> (ENGOT-EN6-NSGO\/GOG-3031) is an ongoing Ph 3 trial in primary advanced (St 3-4) &amp; first recurrent <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> w\/ random assignment 1:1 to <a href=\"https:\/\/twitter.com\/hashtag\/dostarlimab?src=hash&amp;ref_src=twsrc%5Etfw\">#dostarlimab<\/a> (500 mg), or placebo, plus <a href=\"https:\/\/twitter.com\/hashtag\/carboplatin?src=hash&amp;ref_src=twsrc%5Etfw\">#carboplatin<\/a> &amp; <a href=\"https:\/\/twitter.com\/hashtag\/paclitaxel?src=hash&amp;ref_src=twsrc%5Etfw\">#paclitaxel<\/a> . . .<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403972872532196?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">6d) &#8230; so combined with <a href=\"https:\/\/twitter.com\/hashtag\/immunotherapy?src=hash&amp;ref_src=twsrc%5Etfw\">#immunotherapy<\/a> may have synergistic effects in the tumor microenvironment. Proof of concept already published in <a href=\"https:\/\/twitter.com\/NEJM?ref_src=twsrc%5Etfw\">@nejm<\/a>: <a href=\"https:\/\/t.co\/AN8RNIzoaT\">https:\/\/t.co\/AN8RNIzoaT<\/a> <a href=\"https:\/\/t.co\/dAm1sdmthA\">pic.twitter.com\/dAm1sdmthA<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403975896621364?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">7b) Data on <a href=\"https:\/\/twitter.com\/hashtag\/QTWIST?src=hash&amp;ref_src=twsrc%5Etfw\">#QTWIST<\/a> in <a href=\"https:\/\/twitter.com\/hashtag\/RUBY?src=hash&amp;ref_src=twsrc%5Etfw\">#RUBY<\/a> was presented for 3 cohorts: overall safety population, the mismatch repair-deficient\/microsatellite instability-high (<a href=\"https:\/\/twitter.com\/hashtag\/dMMR?src=hash&amp;ref_src=twsrc%5Etfw\">#dMMR<\/a>\/<a href=\"https:\/\/twitter.com\/hashtag\/MSI_H?src=hash&amp;ref_src=twsrc%5Etfw\">#MSI_H<\/a>) population, &amp; the MMR-proficient\/microsatellite-stable (<a href=\"https:\/\/twitter.com\/hashtag\/pMMR?src=hash&amp;ref_src=twsrc%5Etfw\">#pMMR<\/a>\/<a href=\"https:\/\/twitter.com\/hashtag\/MSS?src=hash&amp;ref_src=twsrc%5Etfw\">#MSS<\/a>) cohort.<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403979809907078?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">9a) We also had an update on detailed safety data from <a href=\"https:\/\/twitter.com\/hashtag\/RUBY?src=hash&amp;ref_src=twsrc%5Etfw\">#RUBY<\/a>. This was presented by <a href=\"https:\/\/twitter.com\/hashtag\/AnnikaAuranen?src=hash&amp;ref_src=twsrc%5Etfw\">#AnnikaAuranen<\/a> from <a href=\"https:\/\/twitter.com\/UniTurku?ref_src=twsrc%5Etfw\">@UniTurku<\/a>. <a href=\"https:\/\/t.co\/cAC4r9eAmN\">pic.twitter.com\/cAC4r9eAmN<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403983203041299?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">9c) In the Ph3 <a href=\"https:\/\/twitter.com\/hashtag\/RUBY?src=hash&amp;ref_src=twsrc%5Etfw\">#RUBY<\/a> trial of dostarlimab\/placebo + <a href=\"https:\/\/twitter.com\/hashtag\/carboplatin?src=hash&amp;ref_src=twsrc%5Etfw\">#carboplatin<\/a>\/<a href=\"https:\/\/twitter.com\/hashtag\/paclitaxel?src=hash&amp;ref_src=twsrc%5Etfw\">#paclitaxel<\/a> at this data cut, 5 \u2620\ufe0f were reported, but only two were deemed related to <a href=\"https:\/\/twitter.com\/hashtag\/dostarlimab?src=hash&amp;ref_src=twsrc%5Etfw\">#dostarlimab<\/a>. The most common <a href=\"https:\/\/twitter.com\/hashtag\/TEAEs?src=hash&amp;ref_src=twsrc%5Etfw\">#TEAEs<\/a> were <a href=\"https:\/\/twitter.com\/hashtag\/fatigue?src=hash&amp;ref_src=twsrc%5Etfw\">#fatigue<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/alopecia?src=hash&amp;ref_src=twsrc%5Etfw\">#alopecia<\/a> &amp; <a href=\"https:\/\/twitter.com\/hashtag\/nausea?src=hash&amp;ref_src=twsrc%5Etfw\">#nausea<\/a> &amp; more common Gr3+ AEs were <a href=\"https:\/\/twitter.com\/hashtag\/anemia?src=hash&amp;ref_src=twsrc%5Etfw\">#anemia<\/a> &amp; <a href=\"https:\/\/twitter.com\/hashtag\/neutropenia?src=hash&amp;ref_src=twsrc%5Etfw\">#neutropenia<\/a>: <a href=\"https:\/\/t.co\/k8DFjbmQpw\">pic.twitter.com\/k8DFjbmQpw<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403987078602967?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">10b) DB-1303 = humanized IgG1 <a href=\"https:\/\/twitter.com\/hashtag\/Mab?src=hash&amp;ref_src=twsrc%5Etfw\">#Mab<\/a> (<a href=\"https:\/\/twitter.com\/hashtag\/trastuzumab?src=hash&amp;ref_src=twsrc%5Etfw\">#trastuzumab<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/biosimilar?src=hash&amp;ref_src=twsrc%5Etfw\">#biosimilar<\/a> targeting <a href=\"https:\/\/twitter.com\/hashtag\/HER2?src=hash&amp;ref_src=twsrc%5Etfw\">#HER2<\/a> [BAT0606]), a payload of <a href=\"https:\/\/twitter.com\/hashtag\/DNA?src=hash&amp;ref_src=twsrc%5Etfw\">#DNA<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/topisomerase1?src=hash&amp;ref_src=twsrc%5Etfw\">#topisomerase1<\/a> inhibitor (<a href=\"https:\/\/twitter.com\/hashtag\/P1003?src=hash&amp;ref_src=twsrc%5Etfw\">#P1003<\/a>), &amp; an enzymatically cleavable tetrapeptide-<a href=\"https:\/\/twitter.com\/hashtag\/maleimide?src=hash&amp;ref_src=twsrc%5Etfw\">#maleimide<\/a> linker (<a href=\"https:\/\/twitter.com\/hashtag\/L101P1003?src=hash&amp;ref_src=twsrc%5Etfw\">#L101P1003<\/a>).<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403990673207554?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">11a) At <a href=\"https:\/\/twitter.com\/hashtag\/ESGO2023?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO2023<\/a>, data were presented on 32 <a href=\"https:\/\/twitter.com\/hashtag\/ECpatients?src=hash&amp;ref_src=twsrc%5Etfw\">#ECpatients<\/a>; <a href=\"https:\/\/twitter.com\/hashtag\/histology?src=hash&amp;ref_src=twsrc%5Etfw\">#histology<\/a> included <a href=\"https:\/\/twitter.com\/hashtag\/serous?src=hash&amp;ref_src=twsrc%5Etfw\">#serous<\/a> papillary <a href=\"https:\/\/twitter.com\/hashtag\/carcinoma?src=hash&amp;ref_src=twsrc%5Etfw\">#carcinoma<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/adenocarcinoma?src=hash&amp;ref_src=twsrc%5Etfw\">#adenocarcinoma<\/a>, &amp; <a href=\"https:\/\/twitter.com\/hashtag\/carcinosarcoma?src=hash&amp;ref_src=twsrc%5Etfw\">#carcinosarcoma<\/a>. The latter 2 are more likely to have PD-L1 expression.<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403994477449546?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">11c) Responses were seen in 10\/17 evaluable patients, 50% at 7mg\/kg (n=4) and 61% at 8mg\/kg (n=13). Disease control rate was 94.1%.<br>\ud83e\uddba Most common <a href=\"https:\/\/twitter.com\/hashtag\/TEAEs?src=hash&amp;ref_src=twsrc%5Etfw\">#TEAEs<\/a> of any grade were <a href=\"https:\/\/twitter.com\/hashtag\/vomiting?src=hash&amp;ref_src=twsrc%5Etfw\">#vomiting<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/fatigue?src=hash&amp;ref_src=twsrc%5Etfw\">#fatigue<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/nausea?src=hash&amp;ref_src=twsrc%5Etfw\">#nausea<\/a>, and most common Gr 3 &amp; above TEAEs were <a href=\"https:\/\/twitter.com\/hashtag\/syncope?src=hash&amp;ref_src=twsrc%5Etfw\">#syncope<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/anemia?src=hash&amp;ref_src=twsrc%5Etfw\">#anemia<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/hypokalemia?src=hash&amp;ref_src=twsrc%5Etfw\">#hypokalemia<\/a>. <a href=\"https:\/\/t.co\/VoLN4VWgKi\">pic.twitter.com\/VoLN4VWgKi<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724403997467894089?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">12b) Wrapping up <a href=\"https:\/\/twitter.com\/hashtag\/immunotherapies?src=hash&amp;ref_src=twsrc%5Etfw\">#immunotherapies<\/a> for <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/ESGO2023?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO2023<\/a> new data:<br>\ud83d\udc49new data on <a href=\"https:\/\/twitter.com\/hashtag\/DB_1303?src=hash&amp;ref_src=twsrc%5Etfw\">#DB_1303<\/a>, novel <a href=\"https:\/\/twitter.com\/hashtag\/ADC?src=hash&amp;ref_src=twsrc%5Etfw\">#ADC<\/a> targeting <a href=\"https:\/\/twitter.com\/hashtag\/HER2?src=hash&amp;ref_src=twsrc%5Etfw\">#HER2<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a>:<br>1\u20e3 only (ongoing) Ph 1\/2 trial, but appears to have reasonable safety profile<br>2\u20e3 shows promising anti-<a href=\"https:\/\/twitter.com\/hashtag\/tumor?src=hash&amp;ref_src=twsrc%5Etfw\">#tumor<\/a> activity<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724404000705888584?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">14a) Xhindoli reviewed experience from <a href=\"https:\/\/twitter.com\/hashtag\/tertiary?src=hash&amp;ref_src=twsrc%5Etfw\">#tertiary<\/a> referral center European Institute of Oncology in <a href=\"https:\/\/twitter.com\/hashtag\/Milan?src=hash&amp;ref_src=twsrc%5Etfw\">#Milan<\/a>. They prospectively characterized recurrence-free survival among 4 molecular classes of all cases St 1-3 <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> since April 2019:<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406908142919690?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">14c) Looking at these markers, clinical characteristics, and survival, their data supported previous work that <a href=\"https:\/\/twitter.com\/hashtag\/POLEmut?src=hash&amp;ref_src=twsrc%5Etfw\">#POLEmut<\/a> may have a protective role in <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> &amp; that <a href=\"https:\/\/twitter.com\/hashtag\/p53abn?src=hash&amp;ref_src=twsrc%5Etfw\">#p53abn<\/a> positivity actually portends poorer outcomes. In this study, the overall recurrence rate in 239 pts was 12.1%: <a href=\"https:\/\/t.co\/8R3grWie33\">pic.twitter.com\/8R3grWie33<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406911519391753?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">15b) She looked at <a href=\"https:\/\/twitter.com\/hashtag\/PD1?src=hash&amp;ref_src=twsrc%5Etfw\">#PD1<\/a>, <a href=\"https:\/\/twitter.com\/hashtag\/PDL1?src=hash&amp;ref_src=twsrc%5Etfw\">#PDL1<\/a>, and <a href=\"https:\/\/twitter.com\/hashtag\/IFN%CE%B3?src=hash&amp;ref_src=twsrc%5Etfw\">#IFN\u03b3<\/a>. Interestingly, PD-1 <a href=\"https:\/\/twitter.com\/hashtag\/mRNA?src=hash&amp;ref_src=twsrc%5Etfw\">#mRNA<\/a> levels were ~7x higher in <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> tissue than in controls. PD-L1 immune checkpoint expression in EC tissue was 3x greater, and IFN\u03b3 expression was 5x greater than controls, all P &lt; 0.001.<br>She concluded:<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406915172647030?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">15d) She summarized: <a href=\"https:\/\/twitter.com\/hashtag\/immune?src=hash&amp;ref_src=twsrc%5Etfw\">#immune<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/checkpoint?src=hash&amp;ref_src=twsrc%5Etfw\">#checkpoint<\/a> expression in <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> often correlates with clinical outcomes, and levels of expression should guide treatment strategies <a href=\"https:\/\/t.co\/Tgr0uthFGz\">pic.twitter.com\/Tgr0uthFGz<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406924605624649?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">16b) This trial is recruiting pts w\/ advanced\/recurrent <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> who have received <a href=\"https:\/\/twitter.com\/hashtag\/chemo?src=hash&amp;ref_src=twsrc%5Etfw\">#chemo<\/a> up to 6 cycles \u27a1\ufe0f partial\/complete response &amp; then are randomized to either 1 of 2 doses of <a href=\"https:\/\/twitter.com\/hashtag\/navtemadlin?src=hash&amp;ref_src=twsrc%5Etfw\">#navtemadlin<\/a> in 4-wk cycles vs observation.<br>Ph2 goal = identify optimal Ph3 dose. Ph3 1\u00ba endpoint = PFS <a href=\"https:\/\/t.co\/AWmy0wrVU5\">pic.twitter.com\/AWmy0wrVU5<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406939151388906?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">16d) The study arms being evaluated in this maintenance therapy trial (ENGOT-En21 and GOG-3089) are<br>1\u20e3 180mg <a href=\"https:\/\/twitter.com\/hashtag\/navtemadlin?src=hash&amp;ref_src=twsrc%5Etfw\">#navtemadlin<\/a> per day<br>2\u20e3 240 mg navtemadlin per day<br>3\u20e3 observation<br>Watch this one! <a href=\"https:\/\/t.co\/4YpO9WBJ61\">pic.twitter.com\/4YpO9WBJ61<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406953634308102?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">17b) <a href=\"https:\/\/twitter.com\/hashtag\/Selinexor?src=hash&amp;ref_src=twsrc%5Etfw\">#Selinexor<\/a> is a 1st-in-class, oral Selective Inhibitor of Nuclear Export (<a href=\"https:\/\/twitter.com\/hashtag\/SINE?src=hash&amp;ref_src=twsrc%5Etfw\">#SINE<\/a>) compound. It binds with &amp; inhibits the nuclear export protein <a href=\"https:\/\/twitter.com\/hashtag\/XPO1?src=hash&amp;ref_src=twsrc%5Etfw\">#XPO1<\/a>, \u27a1\ufe0faccumulation of tumor suppressor proteins in the cell nucleus.<br>(Figure from \ud83d\udd13 <a href=\"https:\/\/t.co\/kj6PUOs6CC\">https:\/\/t.co\/kj6PUOs6CC<\/a>) <a href=\"https:\/\/t.co\/ASJz6ZJpPU\">pic.twitter.com\/ASJz6ZJpPU<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406957484687514?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">18a) At <a href=\"https:\/\/twitter.com\/hashtag\/ESGO2023?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO2023<\/a>, J P\u00e9rezFidalgo presented this analysis of long-term f\/u of <a href=\"https:\/\/twitter.com\/hashtag\/selinexor?src=hash&amp;ref_src=twsrc%5Etfw\">#selinexor<\/a> maintenance in pts with <a href=\"https:\/\/twitter.com\/hashtag\/TP53wt?src=hash&amp;ref_src=twsrc%5Etfw\">#TP53wt<\/a> advanced (St 4) or recurrent <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a>. After response to <a href=\"https:\/\/twitter.com\/hashtag\/chemo?src=hash&amp;ref_src=twsrc%5Etfw\">#chemo<\/a> pts are randomized to maintenance selinexor or <a href=\"https:\/\/twitter.com\/hashtag\/placebo?src=hash&amp;ref_src=twsrc%5Etfw\">#placebo<\/a>. <a href=\"https:\/\/t.co\/JjTGKGEvDj\">pic.twitter.com\/JjTGKGEvDj<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406961116979618?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">18c) Most common <a href=\"https:\/\/twitter.com\/hashtag\/TEAEs?src=hash&amp;ref_src=twsrc%5Etfw\">#TEAEs<\/a> of any grade were <a href=\"https:\/\/twitter.com\/hashtag\/nausea?src=hash&amp;ref_src=twsrc%5Etfw\">#nausea<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/vomiting?src=hash&amp;ref_src=twsrc%5Etfw\">#vomiting<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/diarrhea?src=hash&amp;ref_src=twsrc%5Etfw\">#diarrhea<\/a>, &amp; most common Grade 3+ were <a href=\"https:\/\/twitter.com\/hashtag\/neutropenia?src=hash&amp;ref_src=twsrc%5Etfw\">#neutropenia<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/nausea?src=hash&amp;ref_src=twsrc%5Etfw\">#nausea<\/a> &amp; <a href=\"https:\/\/twitter.com\/hashtag\/thrombocytopenia?src=hash&amp;ref_src=twsrc%5Etfw\">#thrombocytopenia<\/a>.<br>\ud83d\udd2dThis work has now advanced to globally enrolling Ph3 ENGOT-EN20, enrolling only pts with <a href=\"https:\/\/twitter.com\/hashtag\/TP53wt?src=hash&amp;ref_src=twsrc%5Etfw\">#TP53wt<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a> after response to initial chemo<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406964719964191?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19b) It\u2019s d . . . see post 14c above. Now, which of the following immune checkpoint molecular expression profiles has been shown to be predictive for <a href=\"https:\/\/twitter.com\/hashtag\/RFS?src=hash&amp;ref_src=twsrc%5Etfw\">#RFS<\/a>?<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406968784216266?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">20) And so you are caught up on the latest data from <a href=\"https:\/\/twitter.com\/hashtag\/ESGO2023?src=hash&amp;ref_src=twsrc%5Etfw\">#ESGO2023<\/a> on advanced &amp; recurrent <a href=\"https:\/\/twitter.com\/hashtag\/endometrial?src=hash&amp;ref_src=twsrc%5Etfw\">#endometrial<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/cancer?src=hash&amp;ref_src=twsrc%5Etfw\">#cancer<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/EC?src=hash&amp;ref_src=twsrc%5Etfw\">#EC<\/a>. Thank you to <a href=\"https:\/\/twitter.com\/DrMeredithGT?ref_src=twsrc%5Etfw\">@DrMeredithGT<\/a> for leading us through all this \ud83c\udd95data! Now you can claim 0.75hr \ud83c\udd93 CE\/<a href=\"https:\/\/twitter.com\/hashtag\/CME?src=hash&amp;ref_src=twsrc%5Etfw\">#CME<\/a> by simply clicking on <a href=\"https:\/\/t.co\/dxtP6Xdl8q\">https:\/\/t.co\/dxtP6Xdl8q<\/a>.<br>Follow us!<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1724406983128715285?ref_src=twsrc%5Etfw\">November 14, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<iframe\n      id=\"JotFormIFrame-233167239608158\"\n      title=\"endometrial3_ESGO2023 | Oncology CE 2023new\"\n      onload=\"window.parent.scrollTo(0,0)\"\n      allowtransparency=\"true\"\n      allowfullscreen=\"true\"\n      allow=\"geolocation; microphone; camera\"\n      src=\"https:\/\/form.jotform.com\/233167239608158\"\n      frameborder=\"0\"\n      style=\"min-width:100%;max-width:100%;height:1539px;border:none;\"\n      scrolling=\"no\"\n    >\n    <\/iframe>\n    <script type=\"text\/javascript\">\n    var ifr = document.getElementById(\"JotFormIFrame-233167239608158\");\n    if (ifr) {\n      var src = ifr.src;\n      var iframeParams = [];\n      if (window.location.href && window.location.href.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(window.location.href.substr(window.location.href.indexOf(\"?\") + 1).split('&'));\n      }\n      if (src && src.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(src.substr(src.indexOf(\"?\") + 1).split(\"&\"));\n        src = src.substr(0, src.indexOf(\"?\"))\n      }\n      iframeParams.push(\"isIframeEmbed=1\");\n      ifr.src = src + \"?\" + iframeParams.join('&');\n    }\n    window.handleIFrameMessage = function(e) {\n      if (typeof e.data === 'object') { return; }\n      var args = e.data.split(\":\");\n      if (args.length > 2) { iframe = document.getElementById(\"JotFormIFrame-\" + args[(args.length - 1)]); } else { iframe = document.getElementById(\"JotFormIFrame\"); }\n      if (!iframe) { return; }\n      switch (args[0]) {\n        case \"scrollIntoView\":\n          iframe.scrollIntoView();\n          break;\n        case \"setHeight\":\n          iframe.style.height = args[1] + \"px\";\n          if (!isNaN(args[1]) && parseInt(iframe.style.minHeight) > parseInt(args[1])) {\n            iframe.style.minHeight = args[1] + \"px\";\n          }\n          break;\n        case \"collapseErrorPage\":\n          if (iframe.clientHeight > window.innerHeight) {\n            iframe.style.height = window.innerHeight + \"px\";\n          }\n          break;\n        case \"reloadPage\":\n          window.location.reload();\n          break;\n        case \"loadScript\":\n          if( !window.isPermitted(e.origin, ['jotform.com', 'jotform.pro']) ) { break; }\n          var src = args[1];\n          if (args.length > 3) {\n              src = args[1] + ':' + args[2];\n          }\n          var script = document.createElement('script');\n          script.src = src;\n          script.type = 'text\/javascript';\n          document.body.appendChild(script);\n          break;\n        case \"exitFullscreen\":\n          if      (window.document.exitFullscreen)        window.document.exitFullscreen();\n          else if (window.document.mozCancelFullScreen)   window.document.mozCancelFullScreen();\n          else if (window.document.mozCancelFullscreen)   window.document.mozCancelFullScreen();\n          else if (window.document.webkitExitFullscreen)  window.document.webkitExitFullscreen();\n          else if (window.document.msExitFullscreen)      window.document.msExitFullscreen();\n          break;\n      }\n      var isJotForm = (e.origin.indexOf(\"jotform\") > -1) ? true : false;\n      if(isJotForm && \"contentWindow\" in iframe && \"postMessage\" in iframe.contentWindow) {\n        var urls = {\"docurl\":encodeURIComponent(document.URL),\"referrer\":encodeURIComponent(document.referrer)};\n        iframe.contentWindow.postMessage(JSON.stringify({\"type\":\"urls\",\"value\":urls}), \"*\");\n      }\n    };\n    window.isPermitted = function(originUrl, whitelisted_domains) {\n      var url = document.createElement('a');\n      url.href = originUrl;\n      var hostname = url.hostname;\n      var result = false;\n      if( typeof hostname !== 'undefined' ) {\n        whitelisted_domains.forEach(function(element) {\n            if( hostname.slice((-1 * element.length - 1)) === '.'.concat(element) ||  hostname === element ) {\n                result = true;\n            }\n        });\n        return result;\n      }\n    };\n    if (window.addEventListener) {\n      window.addEventListener(\"message\", handleIFrameMessage, false);\n    } else if (window.attachEvent) {\n      window.attachEvent(\"onmessage\", handleIFrameMessage);\n    }\n    <\/script>\n","protected":false},"excerpt":{"rendered":"<p>2) This 3\u20e3 rd installment addresses key pertinent data from #ESGO2023, held in #Istanbul last month.#FOAMed #onctwitter #ecsm #gyncancersmFollow us for regular #accredited updates across #oncology, all delivered right here on X ! pic.twitter.com\/Rl9t8Jy4YP &mdash; @onc_ce (@onc_ce) November 14, 2023 4a) @ESGO_society #ESGO23 lived up to its billing as the European Voice of #Gynecological #Oncology. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_mi_skip_tracking":false,"footnotes":""},"categories":[34],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1190"}],"collection":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/comments?post=1190"}],"version-history":[{"count":2,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1190\/revisions"}],"predecessor-version":[{"id":1193,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1190\/revisions\/1193"}],"wp:attachment":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/media?parent=1190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/categories?post=1190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/tags?post=1190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}